Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label TIL + high-dose IL-2 after lymphodepleting chemotherapy for metastatic bladder cancer
MOH_2020-05-03_008898Phase 2Not yet recruiting
- Sponsor
- פרופ' גל מרקל
- Start
- Sep 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GC101 TIL + pembrolizumab, aldesleukin, cyclophosphamide and fludarabine in bladder cancer and transitional cell carcinoma (TCC), sponsored by פרופ' גל מרקל. Primary endpoints: Clinical benefit rate and Safety and tolerability. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
GC101 TIL + pembrolizumabaldesleukincyclophosphamidefludarabine
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2020-05-03_008898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-03_008898.